Charles River Laboratories International, Inc. $CRL Shares Sold by Iridian Asset Management LLC CT

Iridian Asset Management LLC CT cut its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 39.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,626 shares of the medical research company’s stock after selling 18,940 shares during the period. Charles River Laboratories International makes up approximately 1.8% of Iridian Asset Management LLC CT’s investment portfolio, making the stock its 20th biggest position. Iridian Asset Management LLC CT’s holdings in Charles River Laboratories International were worth $4,479,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its position in Charles River Laboratories International by 29.1% in the second quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock worth $353,750,000 after purchasing an additional 516,521 shares during the period. Ariel Investments LLC raised its stake in shares of Charles River Laboratories International by 28.6% in the 2nd quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock worth $214,751,000 after buying an additional 314,572 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Charles River Laboratories International by 11.6% in the second quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company’s stock valued at $187,712,000 after buying an additional 128,785 shares during the period. Bank of America Corp DE boosted its stake in Charles River Laboratories International by 29.2% during the second quarter. Bank of America Corp DE now owns 1,026,013 shares of the medical research company’s stock valued at $155,677,000 after buying an additional 232,020 shares in the last quarter. Finally, Sei Investments Co. grew its holdings in Charles River Laboratories International by 5.9% during the second quarter. Sei Investments Co. now owns 714,688 shares of the medical research company’s stock worth $108,440,000 after acquiring an additional 39,959 shares during the period. Institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

CRL has been the subject of several research reports. Argus set a $200.00 price objective on shares of Charles River Laboratories International in a research report on Monday, November 17th. William Blair raised shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research note on Monday, October 6th. Robert W. Baird set a $224.00 target price on shares of Charles River Laboratories International in a report on Friday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, October 8th. Finally, Barclays increased their price objective on Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $198.79.

Charles River Laboratories International Stock Up 2.6%

CRL stock opened at $221.09 on Monday. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $222.37. The company’s 50 day simple moving average is $187.14 and its 200-day simple moving average is $171.92. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10. The firm has a market capitalization of $10.88 billion, a P/E ratio of -141.72, a P/E/G ratio of 6.60 and a beta of 1.61.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $990.43 million. During the same quarter last year, the business posted $2.59 EPS. The company’s revenue was down .5% on a year-over-year basis. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.